pembrolizumab + DC-CIK cell immunotherapy + hyperthermia

This therapeutic regimen is a novel combination therapy being evaluated by Capital Medical University for the treatment of advanced malignant mesothelioma. It consists of the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda), autologous dendritic cell-cytokine induced killer (DC-CIK) cell immunotherapy, and regional hyperthermia. Pembrolizumab functions as a checkpoint inhibitor by blocking the Programmed Cell Death Protein 1 (PD-1) receptor on T-cells, thereby preventing its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immune activity. The DC-CIK component involves the ex vivo expansion and activation of a patient's own mononuclear cells into a heterogeneous population of immune effectors (including dendritic cells and T-cells) intended to provide direct cytotoxicity and stimulate broader immune responses. Hyperthermia, delivered via the Thermotron RF-8EX device, is used to physically stress tumor cells, potentially increasing their immunogenicity and enhancing the infiltration and efficacy of the immunotherapy components within the tumor microenvironment.

Brand names

Keytruda

Other names

anti-PD-1 antibody-Capital Medical University-malignant mesotheliomaanti-PD1 antibody-Capital Medical University-malignant mesotheliomaanti-PD 1 antibody-Capital Medical University-malignant mesotheliomapembrolizumab + autologous DC-CIK cell immunotherapy + hyperthermiaAnti-PD-1 antibody + DC-CIK Immunotherapy + Thermotron RF-8EX